-
Mashup Score: 5
Join international experts in urothelial cancer, Dr Grande and Dr Kanesvaran, as they discuss phase II and III trials such as IMvigor130, CheckMate 274 and UNITE.
Source: insights.medicinematters.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 3
Join international experts in urothelial cancer, Dr Grande and Dr Kanesvaran, as they discuss phase II and III trials such as IMvigor130, CheckMate 274 and UNITE.
Source: Medicine Matters insightsCategories: Hem/Oncs, Latest HeadlinesTweet-
A great presentation on #GU23 with our @OncoAlert 🚨Colleagues @drenriquegrande & @ravikanesvaran brought to us by Springer Nature Click Link to Watch this supported content: https://t.co/BIzIbzHJER https://t.co/PB2Hjf8Qmb
-
-
Mashup Score: 3
Join international experts in urothelial cancer, Dr Grande and Dr Kanesvaran, as they discuss phase II and III trials such as IMvigor130, CheckMate 274 and UNITE.
Source: Medicine Matters insightsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Out by our Collaborators at Springer Nature: Advances in urothelial cancer treatment and prognosis: Expert-led insights from #GU23 🌐 chaired by our @OncoAlert 🚨 Faculty @drenriquegrande 🇪🇸 Click Link to Watch this supported content: https://t.co/6rVI3UZu6h https://t.co/82vL2oJW0a https://t.co/VybtADwyw1
-
-
Mashup Score: 1FDA approves talazoparib with enzalutamide for HRR gene-mutated metast - 11 month(s) ago
FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer
Categories: Latest Headlines, Partners & KOLsTweet-
Congrats @neerajaiims #karim et al. This is remarkable, adding to the armamentarium for patients! I recall Neeraj stellar talk @ASCO #GU23 ! https://t.co/VUleJW4mLK @NeliMUlrich @huntsmancancer @SWOG @PCFnews @charlesryanmd @OncoAlert @PrimoLaraMD @JessicaHawleyMD @HibaMKhanMD https://t.co/yetbSHiYsy
-
-
Mashup Score: 0
Michael Atkins joins Pedro Barata in a conversation on Cohort A of a phase II study looking at treatment-free survival (TFS) outcomes of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260). This study was designed to potentially reduce the toxicity by sparing people ipi who didn’t need it and also capping therapy in patients who were having a…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
HCRN GU 16-260, nivolumab and salvage nivolumab+ipilimumab in patients with advanced #RenalCellCarcinoma cohort A, treatment-free survival outcomes. Michael Atkins, MD @LombardiCancer joins @PBarataMD @caseccc to discuss his work on UroToday > https://t.co/2MP1YgXwJI #GU23 https://t.co/sfVlyaBfgg
-
-
Mashup Score: 2Cell-Free Urinary DNA Predictive Impact on Patients with Non-Muscle Invasive Bladder Cancer - Kyle Rose - 12 month(s) ago
Kyle Rose joins Sam Chang in discussing his team’s findings regarding the impact of cell-free urinary DNA on non-muscle invasive bladder cancer patients. This study aims to detect tumor alterations or mutations in the urine of high-risk non-invasive bladder cancer patients undergoing a repeat TURBT. Using whole exome sequencing and an ultra-deep sequencing platform, the study found that urinary…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Cell-free urinary DNA predictive impact on patients with non-muscle invasive #BladderCancer. @KyleRoseMD @MoffittNews joins @UroCancerMD @VUMC_Cancer to discuss his team's findings in this conversation on UroToday > https://t.co/BFgdhxRh9k #GU23 @ASCO https://t.co/yaRgUz02ZS
-
-
Mashup Score: 0Immune Checkpoint Inhibitors in Bladder Cancer: Refining Their Role - 12 month(s) ago
Emerging data demonstrate the potential of these drugs to optimize survival, preserve quality of life, and even spare patients a radical cystectomy.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
For muscle-invasive and metastatic bladder cancer, outcomes are grim. Because of this, the approval of immune checkpoint inhibitors was a major milestone for these patients. #blcsm #GU23 | @FoxChaseCancer @TischCancer @MattGalsky @IcahnMountSinai https://t.co/A4RbKdcVCI
-
-
Mashup Score: 1
Michael Atkins joins Pedro Barata in a conversation on Cohort A of a phase II study looking at treatment-free survival (TFS) outcomes of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260). This study was designed to potentially reduce the toxicity by sparing people ipi who didn’t need it and also capping therapy in patients who were having a…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
HCRN GU 16-260, nivolumab and salvage nivolumab+ipilimumab in patients with advanced #RenalCellCarcinoma cohort A, treatment-free survival outcomes. Michael Atkins, MD @LombardiCancer joins @PBarataMD @caseccc to discuss his work on UroToday > https://t.co/2MP1YgXwJI #GU23 https://t.co/tWeeoETLdQ
-
-
Mashup Score: 0Exploratory IMvigor130 Data Support Single-agent Atezolizumab in Select Patients With Urothelial Carcinoma - 1 year(s) ago
Aristotelis Bamias, MD, discusses the efficacy and safety data from the final OS analysis of the IMvigor130 trial and emphasizes the clinical implications of this research in metastatic urothelial cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exploratory IMvigor130 Data Support Single-agent Atezolizumab in Select Patients With Urothelial Carcinoma @ASCO #blcsm #GU23 https://t.co/lZXsOMEuNQ
-
-
Mashup Score: 1Limited Drug Antagonism Between Darolutamide and Docetaxel Confirms Efficacy and Tolerability of ARASENS Triplet in mHSPC - 1 year(s) ago
Bertrand F. Tombal, MD, PhD, explains how data on the clinically relevant drug-drug interactions and TRAEs with darolutamide, docetaxel and ADT support previously reported efficacy data from the ARASENS trial, and presents lingering questions and caveats from this trial that should be addressed through continued research.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Limited Drug Antagonism Between Darolutamide and Docetaxel Confirms Efficacy and Tolerability of ARASENS Triplet in mHSPC @BertrandTOMBAL @ClinUnivStLuc @ASCO #GU23 #pcsm https://t.co/VfZaEOVYCT
-
A great presentation on #GU23 with our @OncoAlert 🚨Colleagues @drenriquegrande & @ravikanesvaran brought to us by Springer Nature Click Link to Watch this supported content: https://t.co/BIzIbzHJER https://t.co/pbtY0Z7kUI